I, too, made comments in January and February regarding the COVID19 indication. I believe I said we didn’t need to waste the time and money on a virus that would pass quickly. Well, I was wrong on the passing of the virus and I hope I’m wrong about leronlimab and COVID19. I’m not convinced that the FDA will grant EUA based on an 84 person trial, but there’s no drug that actually treats COVID19 at this point, so anything is likely. More so when you consider that CYDY is submitting applications to other countries.

More important is how the data from the M2M translated to the severe trial and to patients who may progress to hospitalization, ventilation and death. I suspect the interim analysis of the severe trial will reveal some exciting findings.